Vivo Biosciences Inc. (VBI), an emerging biotech company founded in 2004, is developing new ‘all-human’ bioassay platforms for preclinical research, drug discovery and therapeutics. The company relies on its patented HuBiogel™ technology which emulates the biology of normal and disease tissues in vitro. A series of 3-D or Mini-tumor bioassay systems are developed for rapid analysis of drug efficacy, toxicity and therapy prediction, the major bottlenecks of current DD pipeline. This high-value technology is offered worldwide to academic, private and government institutions.
1601 12th Ave S, Birmingham (AL), 35205, United States